(CercleFinance.com) – Merck and Ridgeback announce that the Japanese Ministry of Health has granted special emergency approval in Japan for molnupiravir, their experimental oral antiviral drug for infectious diseases caused by SARS-CoV-2.
Under a previously announced supply agreement, the Japanese government will purchase 1.6 million molnupiravir treatments from the two pharmaceutical companies to speed up patient access.
‘Molnupiravir, First Oral Covid-19 Antiviral To Be Cleared In The World, Now Cleared In The United States, The United Kingdom And Japan; Regulatory submissions are under review around the world, ‘they say.
Copyright © 2021 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
